RU2008147543A - Агонисты мускариновых рецепторов, эффективные при лечении боли, болезни альцгеймера и шизофрении - Google Patents
Агонисты мускариновых рецепторов, эффективные при лечении боли, болезни альцгеймера и шизофрении Download PDFInfo
- Publication number
- RU2008147543A RU2008147543A RU2008147543/04A RU2008147543A RU2008147543A RU 2008147543 A RU2008147543 A RU 2008147543A RU 2008147543/04 A RU2008147543/04 A RU 2008147543/04A RU 2008147543 A RU2008147543 A RU 2008147543A RU 2008147543 A RU2008147543 A RU 2008147543A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- alkoxy
- heteroaryl
- heterocycloalkyl
- aryl
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims 3
- 201000000980 schizophrenia Diseases 0.000 title claims 3
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 53
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 52
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 50
- 150000002431 hydrogen Chemical class 0.000 claims abstract 48
- 239000001257 hydrogen Substances 0.000 claims abstract 48
- 229910052736 halogen Inorganic materials 0.000 claims abstract 33
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims abstract 32
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 31
- 150000002367 halogens Chemical class 0.000 claims abstract 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 29
- 125000005553 heteroaryloxy group Chemical group 0.000 claims abstract 23
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 13
- 125000002947 alkylene group Chemical group 0.000 claims abstract 12
- -1 C1-6 alkyl halogen Chemical class 0.000 claims abstract 9
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 239000000203 mixture Substances 0.000 claims abstract 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 3
- 125000000217 alkyl group Chemical group 0.000 claims 174
- 125000003545 alkoxy group Chemical group 0.000 claims 133
- 125000001072 heteroaryl group Chemical group 0.000 claims 42
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 32
- 125000003118 aryl group Chemical group 0.000 claims 31
- 125000004104 aryloxy group Chemical group 0.000 claims 22
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims 21
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 12
- PBVFROWIWWGIFK-UHFFFAOYSA-N fluoromethyl-(2-hydroxyethyl)-dimethylazanium Chemical compound FC[N+](C)(C)CCO PBVFROWIWWGIFK-UHFFFAOYSA-N 0.000 claims 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 11
- 238000000034 method Methods 0.000 claims 9
- 125000003282 alkyl amino group Chemical group 0.000 claims 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 230000003993 interaction Effects 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims 1
- DMQNYYUSRGZMNA-IBGZPJMESA-N 1-methyl-3-[1-[(3s)-1-[3-(2-oxopyrrolidin-1-yl)propanoyl]pyrrolidin-3-yl]piperidin-4-yl]benzimidazol-2-one Chemical compound C([C@@H](C1)N2CCC(CC2)N2C3=CC=CC=C3N(C2=O)C)CN1C(=O)CCN1CCCC1=O DMQNYYUSRGZMNA-IBGZPJMESA-N 0.000 claims 1
- WQMADGKABXWRPB-UHFFFAOYSA-N 3-[1-(1-butanoylpyrrolidin-3-yl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1N(C(=O)CCC)CCC1N1CCC(N2C(NC3=CC=CC=C32)=O)CC1 WQMADGKABXWRPB-UHFFFAOYSA-N 0.000 claims 1
- KIKVFRJEORTHAK-SFHVURJKSA-N 3-[1-[(3s)-1-(cyclopentanecarbonyl)pyrrolidin-3-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C([C@H](CC1)N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)N1C(=O)C1CCCC1 KIKVFRJEORTHAK-SFHVURJKSA-N 0.000 claims 1
- JNOJPZRLZGKCBU-LPHOPBHVSA-N 3-[1-[(3s)-1-[(2s)-oxolane-2-carbonyl]pyrrolidin-3-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C([C@H](CC1)N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)N1C(=O)[C@@H]1CCCO1 JNOJPZRLZGKCBU-LPHOPBHVSA-N 0.000 claims 1
- VTIHIQFWUKTACE-UHFFFAOYSA-N 3-[1-[1-(3-methylbutanoyl)pyrrolidin-3-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1N(C(=O)CC(C)C)CCC1N1CCC(N2C(NC3=CC=CC=C32)=O)CC1 VTIHIQFWUKTACE-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- HPTPNUOHRVVTRL-UHFFFAOYSA-N benzyl 3-[4-(2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]pyrrolidine-1-carboxylate Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CN1C(=O)OCC1=CC=CC=C1 HPTPNUOHRVVTRL-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- HXYQHTSHRKZZEB-OAHLLOKOSA-N ethyl (3r)-3-[4-(2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OCC)CC[C@H]1N1CCC(N2C(NC3=CC=CC=C32)=O)CC1 HXYQHTSHRKZZEB-OAHLLOKOSA-N 0.000 claims 1
- HXYQHTSHRKZZEB-HNNXBMFYSA-N ethyl (3s)-3-[4-(2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OCC)CC[C@@H]1N1CCC(N2C(NC3=CC=CC=C32)=O)CC1 HXYQHTSHRKZZEB-HNNXBMFYSA-N 0.000 claims 1
- UGVSPMUTKNEWKD-HNNXBMFYSA-N ethyl (3s)-3-[4-[2-oxo-6-(trifluoromethyl)-3h-benzimidazol-1-yl]piperidin-1-yl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OCC)CC[C@@H]1N1CCC(N2C(NC3=CC=C(C=C32)C(F)(F)F)=O)CC1 UGVSPMUTKNEWKD-HNNXBMFYSA-N 0.000 claims 1
- HXYQHTSHRKZZEB-UHFFFAOYSA-N ethyl 3-[4-(2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OCC)CCC1N1CCC(N2C(NC3=CC=CC=C32)=O)CC1 HXYQHTSHRKZZEB-UHFFFAOYSA-N 0.000 claims 1
- CYPTXTYYWOUWKO-UHFFFAOYSA-N ethyl 3-[4-(5-chloro-2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OCC)CCC1N1CCC(N2C(NC3=CC(Cl)=CC=C32)=O)CC1 CYPTXTYYWOUWKO-UHFFFAOYSA-N 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- PCODWIPXFMYUEX-AWEZNQCLSA-N methyl (3s)-3-[4-(2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC)CC[C@@H]1N1CCC(N2C(NC3=CC=CC=C32)=O)CC1 PCODWIPXFMYUEX-AWEZNQCLSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 claims 1
- 238000006722 reduction reaction Methods 0.000 claims 1
- 238000006268 reductive amination reaction Methods 0.000 claims 1
- VKQFQFLXAGPJKI-INIZCTEOSA-N tert-butyl (3s)-3-[4-(2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC[C@@H]1N1CCC(N2C(NC3=CC=CC=C32)=O)CC1 VKQFQFLXAGPJKI-INIZCTEOSA-N 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 0 *C(N(CC1)CC1=O)=O Chemical compound *C(N(CC1)CC1=O)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81220806P | 2006-06-09 | 2006-06-09 | |
| US60/812,208 | 2006-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008147543A true RU2008147543A (ru) | 2010-07-20 |
Family
ID=38801729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008147543/04A RU2008147543A (ru) | 2006-06-09 | 2007-06-08 | Агонисты мускариновых рецепторов, эффективные при лечении боли, болезни альцгеймера и шизофрении |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100173935A1 (https=) |
| EP (1) | EP2035412A4 (https=) |
| JP (1) | JP2009539833A (https=) |
| KR (1) | KR20090016636A (https=) |
| CN (1) | CN101501024A (https=) |
| AR (1) | AR061306A1 (https=) |
| AU (1) | AU2007256014B2 (https=) |
| BR (1) | BRPI0712415A2 (https=) |
| CA (1) | CA2654147A1 (https=) |
| EC (1) | ECSP088967A (https=) |
| IL (1) | IL195427A0 (https=) |
| MX (1) | MX2008015155A (https=) |
| NO (1) | NO20085271L (https=) |
| RU (1) | RU2008147543A (https=) |
| TW (1) | TW200815405A (https=) |
| UY (1) | UY30393A1 (https=) |
| WO (1) | WO2007142585A1 (https=) |
| ZA (1) | ZA200809976B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200813018A (en) * | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
| TW201322983A (zh) * | 2007-08-31 | 2013-06-16 | Purdue Pharma Lp | 經取代之喹□啉型哌啶化合物及其用途 |
| UY31672A1 (es) * | 2008-02-28 | 2009-09-30 | "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación" | |
| US20090221642A1 (en) * | 2008-03-03 | 2009-09-03 | Astrazeneca Ab | Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176 |
| CN102105465B (zh) | 2008-07-21 | 2015-03-11 | 普渡制药公司 | 取代的喹喔啉型桥连哌啶化合物及其用途 |
| GB0817982D0 (en) * | 2008-10-01 | 2008-11-05 | Glaxo Group Ltd | Compounds |
| WO2012020813A1 (ja) * | 2010-08-10 | 2012-02-16 | 大日本住友製薬株式会社 | 縮環ピロリジン誘導体 |
| CN103764641B (zh) | 2011-05-06 | 2016-10-26 | 扎夫根股份有限公司 | 部分饱和的三环化合物及其制备和使用方法 |
| JP2015083543A (ja) * | 2012-02-14 | 2015-04-30 | 大日本住友製薬株式会社 | 新規縮環ピロリジン誘導体 |
| US20140171466A1 (en) * | 2012-08-14 | 2014-06-19 | Regents Of The University Of Minnesota | Pain management in sickle cell anemia |
| BR112015006029B1 (pt) | 2012-09-18 | 2022-01-25 | Heptares Therapeutics Limited | Compostos aza bicíclicos como agonistas de receptor m1 muscarínicos, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para tratar um distúrbio cognitivo ou distúrbio psicótico ou para tratar ou reduzir a gravidade de dores agudas, crônicas, neuropáticas ou inflamatórias |
| NZ707773A (en) | 2012-11-05 | 2019-05-31 | Zafgen Inc | Methods of treating liver diseases |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5524326A (en) * | 1993-01-21 | 1996-06-11 | Markowitz; Eli | Interactive game between pet and owner |
| JP2002515008A (ja) * | 1994-10-27 | 2002-05-21 | メルク エンド カンパニー インコーポレーテッド | ムスカリン・アンタゴニスト |
| US5756508A (en) * | 1995-10-31 | 1998-05-26 | Merck & Co., Inc. | Muscarine antagonists |
| AU2307999A (en) * | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| ATE275141T1 (de) * | 1999-10-13 | 2004-09-15 | Banyu Pharma Co Ltd | Substituierte imidazolin-derivate |
| JPWO2002085890A1 (ja) * | 2001-04-20 | 2004-08-12 | 萬有製薬株式会社 | ベンズイミダゾロン誘導体 |
| WO2004089942A2 (en) * | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| JP2005532361A (ja) * | 2002-06-17 | 2005-10-27 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症の治療用の眼科用組成物 |
| WO2004069828A1 (ja) * | 2003-02-04 | 2004-08-19 | Mitsubishi Pharma Corporation | ピペリジン化合物およびその医薬用途 |
| KR100869616B1 (ko) * | 2004-05-12 | 2008-11-21 | 화이자 프로덕츠 인코포레이티드 | 프롤린 유도체 및 그의 다이펩티딜 펩티다제－ｉｖ저해제로서의 용도 |
| AU2005249494A1 (en) * | 2004-05-28 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| TW200815351A (en) * | 2006-05-02 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
| TW200813018A (en) * | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
| US8119661B2 (en) * | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| UY31672A1 (es) * | 2008-02-28 | 2009-09-30 | "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación" | |
| US20090221642A1 (en) * | 2008-03-03 | 2009-09-03 | Astrazeneca Ab | Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176 |
| US20090275574A1 (en) * | 2008-05-05 | 2009-11-05 | Astrazeneca Ab | Novel compounds-300 |
-
2007
- 2007-05-29 TW TW096119136A patent/TW200815405A/zh unknown
- 2007-06-06 UY UY30393A patent/UY30393A1/es unknown
- 2007-06-08 JP JP2009514233A patent/JP2009539833A/ja active Pending
- 2007-06-08 US US12/303,641 patent/US20100173935A1/en not_active Abandoned
- 2007-06-08 RU RU2008147543/04A patent/RU2008147543A/ru not_active Application Discontinuation
- 2007-06-08 KR KR1020097000416A patent/KR20090016636A/ko not_active Withdrawn
- 2007-06-08 AR ARP070102508A patent/AR061306A1/es unknown
- 2007-06-08 WO PCT/SE2007/000556 patent/WO2007142585A1/en not_active Ceased
- 2007-06-08 CA CA002654147A patent/CA2654147A1/en not_active Abandoned
- 2007-06-08 MX MX2008015155A patent/MX2008015155A/es not_active Application Discontinuation
- 2007-06-08 BR BRPI0712415-5A patent/BRPI0712415A2/pt not_active IP Right Cessation
- 2007-06-08 EP EP07748219A patent/EP2035412A4/en not_active Withdrawn
- 2007-06-08 AU AU2007256014A patent/AU2007256014B2/en not_active Expired - Fee Related
- 2007-06-08 CN CNA2007800294554A patent/CN101501024A/zh active Pending
-
2008
- 2008-11-20 IL IL195427A patent/IL195427A0/en unknown
- 2008-11-24 ZA ZA2008/09976A patent/ZA200809976B/en unknown
- 2008-12-12 EC EC2008008967A patent/ECSP088967A/es unknown
- 2008-12-16 NO NO20085271A patent/NO20085271L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2035412A1 (en) | 2009-03-18 |
| KR20090016636A (ko) | 2009-02-16 |
| WO2007142585A1 (en) | 2007-12-13 |
| NO20085271L (no) | 2009-01-06 |
| AR061306A1 (es) | 2008-08-20 |
| CA2654147A1 (en) | 2007-12-13 |
| AU2007256014A1 (en) | 2007-12-13 |
| ZA200809976B (en) | 2011-04-28 |
| UY30393A1 (es) | 2009-04-30 |
| MX2008015155A (es) | 2008-12-12 |
| US20100173935A1 (en) | 2010-07-08 |
| AU2007256014B2 (en) | 2011-06-30 |
| JP2009539833A (ja) | 2009-11-19 |
| CN101501024A (zh) | 2009-08-05 |
| IL195427A0 (en) | 2009-08-03 |
| ECSP088967A (es) | 2009-01-30 |
| TW200815405A (en) | 2008-04-01 |
| BRPI0712415A2 (pt) | 2012-09-04 |
| EP2035412A4 (en) | 2011-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008147543A (ru) | Агонисты мускариновых рецепторов, эффективные при лечении боли, болезни альцгеймера и шизофрении | |
| JP2009539833A5 (https=) | ||
| RU2347778C2 (ru) | Новые антагонисты р2х7 рецепторов, способ их получения, фармацевтическая композиция, способ лечения и применение на их основе | |
| RU2437882C2 (ru) | Производные имидазолидинона | |
| RU2216545C2 (ru) | Гетероарил-1-пиперидины и пиперазины, фармацевтическая композиция на их основе, способ лечения психозов и ослабления боли | |
| AU777961B2 (en) | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | |
| RU2320657C2 (ru) | Новые производные пирролидиния | |
| RU2000129161A (ru) | Производное 1-[(1-замещенного-4-пиперидинил)метил]-4-пиперидина, способ его получения, фармацевтическая композиция, содержащая указанное соединение, и промежуточный продукт | |
| DE60107221T2 (de) | Indolin-2-on derivate und deren verwendung als liganden der ocytocin rezeptoren | |
| ES2327620T3 (es) | Derivado de 4,4-difluoro-1,2,3,4-tetraidro-5h-1-benzacepina o sales del mismo. | |
| JP2009530274A5 (https=) | ||
| PE20091090A1 (es) | Derivados de piperidina como agonistas de receptores muscarinicos | |
| JP2012522056A5 (https=) | ||
| RU2011146059A (ru) | Конденсированное пирролопиридиновое производное | |
| US20030236267A1 (en) | Benzimidazole derivatives | |
| RU2008147542A (ru) | Агонисты мускариновых рецепторов, эффективные при лечении боли, болезни альцгеймера и шизофрении | |
| JP2010539151A5 (https=) | ||
| RU2006141320A (ru) | Новые соединения | |
| JP2005509624A5 (https=) | ||
| PE20081837A1 (es) | Derivados de quinuclinidol como antagonistas de los receptores muscarinicos | |
| RU2008139479A (ru) | Производные бензимидазол-5-сульфонамида в качестве лигандов каннабиноидного рецептора 1 (св1) | |
| JP2012507525A5 (https=) | ||
| RU2004121688A (ru) | 7-аминобензотиазольные производные в качестве лигандов аденозинового рецептора | |
| RU2403250C2 (ru) | Производные пиперидин-4-иламида и их применение в качестве антагонистов рецептора sst подтипа 5 | |
| PE20070355A1 (es) | Antagonistas de cgrp seleccionados y procedimientos para su preparacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20120625 |